아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염
    21.
    发明公开
    아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 有权
    具有ADAMANTYL GROUP的药物及其药物可接受的盐

    公开(公告)号:KR1020120111965A

    公开(公告)日:2012-10-11

    申请号:KR1020120004235

    申请日:2012-01-13

    Abstract: PURPOSE: A sulfamie derivative is provided to have excellent restraining activity to 11B-hydroxysteroid dehydrogenase type 1 and to be useful for preventing and treating various diseases mediated by 11B-HSD1. CONSTITUTION: A sulfamie derivative and pharmaceutically acceptable salts thereof are represented by chemical formula 1. In chemical formula 1, R^1 is H, C1-6 alkyl, cyano C1-6 alkyl, C3-8 cycloalkyl, substituted or unsubstituted benzyl, phenylethyl, C1-6 alkoxycarbonyl, phenylacetyl, naphthyl, or aryl of substituted 5-10 membered ring, R^2 and R^3 is respectively C1-6 alkyl or C2-6 alkenyl or R^2 and R^3 forms a ring, R^4 and R^5 is respectively H or C1-C^ alkyl, R^6 is H, OH, COOR^7 or CONR^7R^7, R^7 is H or C1-6 alkyl, and n is an integer from 1-3.

    Abstract translation: 目的:提供一种磺胺衍生物,对1型11B-羟类固醇脱氢酶具有优异的抑制活性,可用于预防和治疗11B-HSD1介导的各种疾病。 组成:氨基磺酸衍生物及其药学上可接受的盐由化学式1表示。在化学式1中,R 1是H,C 1-6烷基,氰基C 1-6烷基,C 3-8环烷基,取代或未取代的苄基,苯乙基 C 1-6烷氧基羰基,苯乙酰基,萘基或被取代的5-10元环的芳基,R 2和R 3分别是C 1-6烷基或C 2-6烯基,或者R 2和R 3形成环, R 4和R 5分别是H或C 1 -C 12烷基,R 6是H,OH,COOR 7或CONR 7 R 17,R 7是H或C 1-6烷基,n是 1-3的整数。

    클로로이미다졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물
    23.
    发明公开
    클로로이미다졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물 失效
    用于预防或治疗包含氯霉素衍生物的药物或药物的药物组合物或其作为活性成分的药物可接受的盐

    公开(公告)号:KR1020100130015A

    公开(公告)日:2010-12-10

    申请号:KR1020090048661

    申请日:2009-06-02

    Abstract: PURPOSE: A pharmaceutical composition containing chloroimidazole derivative for preventing or treating osteoporosis, obesity, diabetes or hyperlipidemia is provided to control TAZ(transcriptional coactivator with PDZbinding motif) protein. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains a compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for obesity, diabetes or hyperlipidemia contains the compound or pharmaceutically acceptable salt as an active ingredient. The compound is chloroimidazole derivatives.

    Abstract translation: 目的:提供含有用于预防或治疗骨质疏松症,肥胖,糖尿病或高脂血症的氯咪唑衍生物的药物组合物以控制TAZ(具有PDZ结合基序的转录共激活物)蛋白质。 构成:用于预防或治疗骨质疏松症的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。 用于肥胖,糖尿病或高脂血症的药物组合物含有化合物或药学上可接受的盐作为活性成分。 该化合物是氯咪唑衍生物。

    싸이아졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적조성물
    25.
    发明公开
    싸이아졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적조성물 失效
    噻唑衍生物,其制备方法及包括其的药物组合物

    公开(公告)号:KR1020080016249A

    公开(公告)日:2008-02-21

    申请号:KR1020060078095

    申请日:2006-08-18

    Abstract: A novel thiazole derivative is provided to inhibit effectively the enzymatic activity of 5-lipoxygenase(5-LO) acting when an arachidonic acid is converted into a leukotriene metabolite, thereby being used as a prophylactic and therapeutic agent of various inflammatory diseases and cancers. A thiazole derivative is represented by the formula(1), wherein each R1 and R2 is independently H, OR7, NO2, halogen or C1-4 linear, branched, or cyclic alkyl; each R3, R4, R5 and R6 is independently H, CF3, OR7, CO2R7, NR7R8, NO2, NHCOR7, C(=O)R7, SR7, halogen, C1-4 linear, branched or cyclic alkyl(in which each R7 and R8 is independently H, unsubstituted or F-substituted C1-6 linear, branched, or cyclic alkyl, or aryl); X is NH, O, S or SO2; Y is C or N. A method for preparing a thiazole derivative represented by the formula(1a) comprises a step of reacting an acetophenone derivative represented by the formula(2) with an aniline derivative represented by the formula(2) and a thiocyanate salt, wherein the R1 to R6, and Y are same as defined above. A pharmaceutical composition for preventing or treating asthma, chronic obstructive lung disease, arthritis, psoriasis, atopic dermatitis, allergy, enteritis, and cancer comprises the thiazole derivative, or a pharmaceutically acceptable salt thereof, a hydrate, solvate or isomer thereof as an effective ingredient.

    Abstract translation: 提供了一种新的噻唑衍生物,用于有效地抑制花生四烯酸转化为白三烯代谢物时作用的5-脂氧合酶(5-LO)的酶活性,从而用作各种炎性疾病和癌症的预防和治疗剂。 噻唑衍生物由式(1)表示,其中每个R 1和R 2独立地为H,OR 7,NO 2,卤素或C 1-4直链,支链或环状烷基; 每个R 3,R 4,R 5和R 6独立地是H,CF 3,OR 7,CO 2 R 7,NR 7 R 8,NO 2,NHCOR 7,C(= O)R 7,SR 7,卤素,C 1-4直链,支链或环状烷基(其中每个R 7和 R8独立地是H,未取代的或F-取代的C 1-6直链,支链或环状烷基或芳基); X是NH,O,S或SO 2; Y为C或N.由式(1a)表示的噻唑衍生物的制备方法包括使式(2)表示的苯乙酮衍生物与式(2)表示的苯胺衍生物和硫氰酸盐 ,其中R1至R6和Y与上述定义相同。 用于预防或治疗哮喘,慢性阻塞性肺病,关节炎,牛皮癣,特应性皮炎,过敏,肠炎和癌症的药物组合物包含噻唑衍生物或其药学上可接受的盐,其水合物,溶剂化物或异构体作为有效成分 。

    신규한 3-인돌리논 유도체 및 이를 포함하는 조성물
    29.
    发明公开
    신규한 3-인돌리논 유도체 및 이를 포함하는 조성물 有权
    新的3-吲哚啉酮衍生物和包含其的组合物

    公开(公告)号:KR1020120065926A

    公开(公告)日:2012-06-21

    申请号:KR1020110086551

    申请日:2011-08-29

    Abstract: PURPOSE: A composition containing a novel 3-indolinone derivative is provided to selectively stain fluorescence to fat and to be used as a diagnosis reagent. CONSTITUTION: A 3-indolinone derivative is denoted by chemical formula 1 or 2. A composition for fluorescence dyeing contains the derivative or salt thereof as an active ingredient. The concentration of the derivative or salt thereof is 1-100 uM. The composition is used for straining fluorescent to fat and diagnosing organism. A kit for detecting lipid contains the derivative or salt thereof as an active ingredient. A kit for diagnosing metabolic diseases contains the derivatives or salt thereof as an active ingredient.

    Abstract translation: 目的:提供含有新的3-二氢吲哚酮衍生物的组合物,以选择性地将荧光染色成脂肪并用作诊断试剂。 构成:3-二氢吲哚酮衍生物由化学式1或2表示。荧光染色用组合物含有作为活性成分的衍生物或其盐。 其衍生物或盐的浓度为1-100uM。 该组合物用于使荧光变为脂肪并诊断生物体。 用于检测脂质的试剂盒含有其衍生物或其盐作为活性成分。 用于诊断代谢疾病的试剂盒含有作为活性成分的衍生物或其盐。

Patent Agency Ranking